Form 8-K - Current report:
SEC Accession No. 0000950170-23-039816
Filing Date
2023-08-08
Accepted
2023-08-08 16:12:23
Documents
14
Period of Report
2023-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acor-20230808.htm   iXBRL 8-K 53996
2 EX-99.1 acor-ex99_1.htm EX-99.1 511430
3 GRAPHIC img123754176_0.jpg GRAPHIC 6064
  Complete submission text file 0000950170-23-039816.txt   709790

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acor-20230808_pre.xml EX-101.PRE 9839
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acor-20230808.xsd EX-101.SCH 2463
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acor-20230808_lab.xml EX-101.LAB 13360
8 EXTRACTED XBRL INSTANCE DOCUMENT acor-20230808_htm.xml XML 4711
Mailing Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965
Business Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965 914-347-4300
Acorda Therapeutics, Inc. (Filer) CIK: 0001008848 (see all company filings)

EIN.: 133831168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31938 | Film No.: 231151437
SIC: 2836 Biological Products, (No Diagnostic Substances)